Avadel Pharmaceuticals to be Sold to Alkermes for $18.50 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 12 2025
0mins
Should l Buy ALKS?
Source: PRnewswire
- Transaction Price Analysis: Avadel Pharmaceuticals is proposed to be sold to Alkermes for $18.50 per share, with an additional contingent cash payment of $1.50 per share dependent on FDA approval of LUMRYZ™ by the end of 2028, which may undervalue the company.
- Legal Investigation Initiated: Former Louisiana Attorney General Charles C. Foti, Jr. and his law firm are investigating the adequacy of this transaction, aiming to ensure shareholders receive fair terms, which could affect shareholder acceptance of the deal.
- FDA Approval Impact: The FDA approval of LUMRYZ™ is a critical condition for the additional cash payment; failure to secure this approval could prevent shareholders from receiving the extra payment, thereby impacting the company's future financial performance.
- Shareholder Rights Protection: KSF law firm is urging shareholders to consider the potential undervaluation in this transaction and offers legal consultation services, demonstrating a commitment to protecting shareholder interests.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALKS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALKS
Wall Street analysts forecast ALKS stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 33.290
Low
37.00
Averages
46.20
High
58.00
Current: 33.290
Low
37.00
Averages
46.20
High
58.00
About ALKS
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alkermes Acquires Avadel to Expand Product Portfolio
- Acquisition Completed: Alkermes has completed its acquisition of Avadel, adding the FDA-approved product LUMRYZ® to its portfolio, which is expected to be accretive in 2026, significantly enhancing the company's competitiveness in the sleep medicine market.
- Market Potential: LUMRYZ® targets over 50,000 eligible patients in the U.S., which is anticipated to drive Alkermes' revenue growth and further solidify its leadership position in the treatment of neurological disorders.
- Financial Arrangement: The acquisition cost approximately $775 million in cash and $1.525 billion in term loans, which Alkermes expects to pay down quickly with cash flows from the business, enhancing financial stability.
- Strategic Development: The acquisition will accelerate Alkermes' entry into the sleep medicine market and support its upcoming clinical development, particularly the planned phase 3 program for narcolepsy.
See More
Goldman Sachs Downgrades Super Micro Computer to Sell with $26 Price Target
- Rating Downgrade: Goldman Sachs analyst Katherine Murphy initiated coverage of Super Micro Computer (NASDAQ:SMCI) on January 13 with a Sell rating and a price target of $26, reflecting a pessimistic outlook that may lead to decreased investor confidence.
- Merger Approval: Shareholders of Huntington Bancshares (NASDAQ:HBAN) and Cadence Bank approved their pending merger on January 6, which is expected to enhance market competitiveness and resource integration, driving future business growth.
- Analyst Support: Multiple analysts initiated coverage of Medline Inc. (NASDAQ:MDLN) on January 12 with bullish ratings, indicating a positive market sentiment towards the company's prospects that could attract more investor interest.
- Market Reaction: Super Micro Computer's shares jumped 11.1% to settle at $32.66 on Friday, indicating mixed market reactions to Jim Cramer's sell recommendation, which may influence subsequent investment decisions.
See More
ImmunityBio (IBRX) Shares Surge 39.8% on Positive QUILT-106 Study Data
- Efficacy Data Update: ImmunityBio's updated efficacy and safety data from the QUILT-106 clinical study show that patients receiving CD19 CAR-NK therapy achieved 100% disease control over 15 months, significantly enhancing the company's competitive position in the Waldenström non-Hodgkin lymphoma space.
- Innovative Treatment Regimen: The study's use of CD19 CAR-NK cells combined with Roche's Rituxan allows outpatient treatment without chemotherapy, highlighting the therapy's strategic importance in terms of patient-friendliness and scalability.
- Strong Market Reaction: ImmunityBio's stock surged 106% over the past six months, significantly outpacing the industry's 22.1% growth, reflecting strong market confidence in its new therapy and positive investor sentiment.
- Future Development Plans: ImmunityBio aims to submit a biologics license application to the FDA by the end of 2026, with full enrollment in the QUILT-2.005 study expected to further bolster the company's market position in treating BCG-unresponsive bladder cancer.
See More
Alkermes Receives FDA Breakthrough Therapy Designation for Alixorexton, Potentially Accelerating Development
- FDA Designation Impact: Alkermes' alixorexton has received Breakthrough Therapy designation from the FDA based on positive data from the Vibrance-1 study, which could enhance the company's competitive position in the sleep disorder market by improving existing narcolepsy treatments.
- R&D Outlook: This designation not only serves as a near-term catalyst for Alkermes' orexin agonist portfolio but may also accelerate development across multiple sleep disorders, bolstering investor confidence in the company's potential for revenue diversification.
- Financial Projections: Alkermes projects $1.4 billion in revenue and $169 million in earnings by 2028, indicating a 1.3% annual revenue decline; however, the Breakthrough Therapy recognition could reshape market perceptions of its long-term profitability.
- Investor Focus: With the FDA's endorsement, investors should closely monitor the significant impact of clinical and regulatory outcomes on Alkermes' long-term earnings, which could materially influence its stock price and market valuation.
See More
Super Micro Computer Rated Sell, Medline Rated Buy by Analysts
- Super Micro Computer Rating: Analysts have rated Super Micro Computer as a sell, indicating concerns about its future performance, which could lead to decreased investor confidence and negatively impact its stock price.
- Alkermes Stock Recommendation: Alkermes has been rated as not recommended by analysts, reflecting skepticism about its growth potential, which may affect its ability to raise capital and overall market performance.
- Medline Investment Outlook: Medline is strongly recommended as a buy by analysts, who describe its stock performance as 'unbelievable', potentially attracting more investor interest and driving its stock price higher.
- STMicroelectronics Investment Advice: STMicroelectronics is viewed as cheap and performing well, with analysts suggesting a buy, which could attract value investors and enhance its market position.
See More
Guess, NESR, and Alkermes Rated Buy with Strong Value Characteristics
- Guess Earnings Estimate Up: Guess, Inc. (GES) holds a Zacks Rank #1, with its current year earnings estimate rising by 5.6% over the past 60 days, indicating strong growth potential in the apparel sector that may enhance its market competitiveness.
- National Energy Services Growth: National Energy Services Reunited Corp. (NESR) also carries a Zacks Rank #1, with next year's earnings estimate increasing by 4.1% in the last 60 days, reflecting a recovery trend in the oilfield services industry that could drive stock price appreciation.
- Alkermes Earnings Forecast Improvement: Alkermes plc (ALKS) maintains a Zacks Rank #1, with its current year earnings estimate up by 3.1% over the past 60 days, suggesting that ongoing innovations in the biopharmaceutical sector will enhance its investment appeal.
- Strong Value Scores: All three companies exhibit low price-to-earnings ratios, with Guess at 9.93, NESR at 11.85, and Alkermes at 19.23, all below their industry averages, highlighting their investment value and attracting more attention from value investors.
See More
Alkermes Acquires Avadel to Expand Product Portfolio
- Acquisition Completed: Alkermes has completed its acquisition of Avadel, adding the FDA-approved product LUMRYZ® to its portfolio, which is expected to be accretive in 2026, significantly enhancing the company's competitiveness in the sleep medicine market.
- Market Potential: LUMRYZ® targets over 50,000 eligible patients in the U.S., which is anticipated to drive Alkermes' revenue growth and further solidify its leadership position in the treatment of neurological disorders.
- Financial Arrangement: The acquisition cost approximately $775 million in cash and $1.525 billion in term loans, which Alkermes expects to pay down quickly with cash flows from the business, enhancing financial stability.
- Strategic Development: The acquisition will accelerate Alkermes' entry into the sleep medicine market and support its upcoming clinical development, particularly the planned phase 3 program for narcolepsy.
See More
Goldman Sachs Downgrades Super Micro Computer to Sell with $26 Price Target
- Rating Downgrade: Goldman Sachs analyst Katherine Murphy initiated coverage of Super Micro Computer (NASDAQ:SMCI) on January 13 with a Sell rating and a price target of $26, reflecting a pessimistic outlook that may lead to decreased investor confidence.
- Merger Approval: Shareholders of Huntington Bancshares (NASDAQ:HBAN) and Cadence Bank approved their pending merger on January 6, which is expected to enhance market competitiveness and resource integration, driving future business growth.
- Analyst Support: Multiple analysts initiated coverage of Medline Inc. (NASDAQ:MDLN) on January 12 with bullish ratings, indicating a positive market sentiment towards the company's prospects that could attract more investor interest.
- Market Reaction: Super Micro Computer's shares jumped 11.1% to settle at $32.66 on Friday, indicating mixed market reactions to Jim Cramer's sell recommendation, which may influence subsequent investment decisions.
See More
ImmunityBio (IBRX) Shares Surge 39.8% on Positive QUILT-106 Study Data
- Efficacy Data Update: ImmunityBio's updated efficacy and safety data from the QUILT-106 clinical study show that patients receiving CD19 CAR-NK therapy achieved 100% disease control over 15 months, significantly enhancing the company's competitive position in the Waldenström non-Hodgkin lymphoma space.
- Innovative Treatment Regimen: The study's use of CD19 CAR-NK cells combined with Roche's Rituxan allows outpatient treatment without chemotherapy, highlighting the therapy's strategic importance in terms of patient-friendliness and scalability.
- Strong Market Reaction: ImmunityBio's stock surged 106% over the past six months, significantly outpacing the industry's 22.1% growth, reflecting strong market confidence in its new therapy and positive investor sentiment.
- Future Development Plans: ImmunityBio aims to submit a biologics license application to the FDA by the end of 2026, with full enrollment in the QUILT-2.005 study expected to further bolster the company's market position in treating BCG-unresponsive bladder cancer.
See More
Alkermes Receives FDA Breakthrough Therapy Designation for Alixorexton, Potentially Accelerating Development
- FDA Designation Impact: Alkermes' alixorexton has received Breakthrough Therapy designation from the FDA based on positive data from the Vibrance-1 study, which could enhance the company's competitive position in the sleep disorder market by improving existing narcolepsy treatments.
- R&D Outlook: This designation not only serves as a near-term catalyst for Alkermes' orexin agonist portfolio but may also accelerate development across multiple sleep disorders, bolstering investor confidence in the company's potential for revenue diversification.
- Financial Projections: Alkermes projects $1.4 billion in revenue and $169 million in earnings by 2028, indicating a 1.3% annual revenue decline; however, the Breakthrough Therapy recognition could reshape market perceptions of its long-term profitability.
- Investor Focus: With the FDA's endorsement, investors should closely monitor the significant impact of clinical and regulatory outcomes on Alkermes' long-term earnings, which could materially influence its stock price and market valuation.
See More
Super Micro Computer Rated Sell, Medline Rated Buy by Analysts
- Super Micro Computer Rating: Analysts have rated Super Micro Computer as a sell, indicating concerns about its future performance, which could lead to decreased investor confidence and negatively impact its stock price.
- Alkermes Stock Recommendation: Alkermes has been rated as not recommended by analysts, reflecting skepticism about its growth potential, which may affect its ability to raise capital and overall market performance.
- Medline Investment Outlook: Medline is strongly recommended as a buy by analysts, who describe its stock performance as 'unbelievable', potentially attracting more investor interest and driving its stock price higher.
- STMicroelectronics Investment Advice: STMicroelectronics is viewed as cheap and performing well, with analysts suggesting a buy, which could attract value investors and enhance its market position.
See More
Guess, NESR, and Alkermes Rated Buy with Strong Value Characteristics
- Guess Earnings Estimate Up: Guess, Inc. (GES) holds a Zacks Rank #1, with its current year earnings estimate rising by 5.6% over the past 60 days, indicating strong growth potential in the apparel sector that may enhance its market competitiveness.
- National Energy Services Growth: National Energy Services Reunited Corp. (NESR) also carries a Zacks Rank #1, with next year's earnings estimate increasing by 4.1% in the last 60 days, reflecting a recovery trend in the oilfield services industry that could drive stock price appreciation.
- Alkermes Earnings Forecast Improvement: Alkermes plc (ALKS) maintains a Zacks Rank #1, with its current year earnings estimate up by 3.1% over the past 60 days, suggesting that ongoing innovations in the biopharmaceutical sector will enhance its investment appeal.
- Strong Value Scores: All three companies exhibit low price-to-earnings ratios, with Guess at 9.93, NESR at 11.85, and Alkermes at 19.23, all below their industry averages, highlighting their investment value and attracting more attention from value investors.
See More
